Lipocine (NASDAQ:LPCN) Issues Quarterly Earnings Results, Beats Estimates By $0.08 EPS

Lipocine (NASDAQ:LPCN) announced its quarterly earnings data on Tuesday. The specialty pharmaceutical company reported ($0.32) earnings per share for the quarter, beating analysts’ consensus estimates of ($0.40) by $0.08, FiscalAI reports. The company had revenue of $0.19 million during the quarter, compared to analyst estimates of $0.21 million. Lipocine had a negative net margin of 755.39% and a negative return on equity of 69.11%.

Lipocine Price Performance

NASDAQ LPCN traded down $0.01 during midday trading on Thursday, hitting $2.16. 13,929 shares of the company traded hands, compared to its average volume of 226,706. Lipocine has a 52 week low of $1.81 and a 52 week high of $12.37. The company’s 50-day simple moving average is $2.27 and its 200-day simple moving average is $4.74. The company has a market cap of $17.80 million, a PE ratio of -1.21 and a beta of 0.46.

Wall Street Analyst Weigh In

Several analysts have recently weighed in on the stock. Wall Street Zen raised shares of Lipocine from a “sell” rating to a “hold” rating in a research note on Saturday, July 18th. Weiss Ratings lowered Lipocine from a “sell (d-)” rating to a “sell (e+)” rating in a research report on Thursday, June 18th. One investment analyst has rated the stock with a Strong Buy rating, one has given a Hold rating and one has assigned a Sell rating to the stock. According to data from MarketBeat.com, Lipocine has a consensus rating of “Hold” and an average target price of $15.00.

Institutional Trading of Lipocine

Several hedge funds have recently modified their holdings of LPCN. Citadel Advisors LLC acquired a new stake in Lipocine in the third quarter valued at approximately $41,000. Jane Street Group LLC acquired a new stake in shares of Lipocine in the 4th quarter worth $85,000. Renaissance Technologies LLC grew its stake in Lipocine by 3.6% during the 4th quarter. Renaissance Technologies LLC now owns 37,397 shares of the specialty pharmaceutical company’s stock worth $300,000 after buying an additional 1,300 shares during the last quarter. Boothbay Fund Management LLC acquired a new position in Lipocine during the 4th quarter valued at about $441,000. Finally, Geode Capital Management LLC raised its stake in Lipocine by 2.2% in the fourth quarter. Geode Capital Management LLC now owns 62,450 shares of the specialty pharmaceutical company’s stock valued at $502,000 after buying an additional 1,374 shares during the last quarter. 9.11% of the stock is owned by hedge funds and other institutional investors.

Lipocine Company Profile

Lipocine Inc is a clinical-stage pharmaceutical company focused on the development and commercialization of oral drug delivery technologies. The company’s core expertise lies in lipid-based formulations designed to improve the bioavailability of therapeutics that traditionally require injectable administration. By leveraging proprietary technologies, Lipocine aims to offer patient-friendly alternatives with the potential for more consistent pharmacokinetic profiles and improved compliance.

The company’s lead product, TLANDO (LPCN 1021), is an oral testosterone replacement therapy approved by the U.S.